GlassScriptPhysician profile
Walter Hooper
NPI 1649760067
$2,008.44
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $478 · 2023: $493 · 2024: $270 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.89 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $205.83 | 2023 | |
| Nestle Healthcare Nutrition INC. | $169.81 | 2021-2023 | |
| Glaxosmithkline, LLC. | $128.81 | 2021-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.00 | 2023-2024 | Xifaxan, Trulance |
| Amgen INC. | $74.64 | 2022-2025 | Evenity, Prolia, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $57.45 | 2022 | |
| Esperion Therapeutics, INC. | $55.63 | 2023-2024 | Nexletol |
| Lilly USA, LLC | $36.95 | 2022-2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $34.62 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $31.33 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.63 | 2021 | |
| Ironwood Pharmaceuticals, INC | $21.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.93 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $20.83 | 2025 | Aptima |
| Idorsia Pharmaceuticals US INC | $20.37 | 2023 | Quviviq |
| Novo Nordisk INC | $20.33 | 2025 | Wegovy |
| Abbott Laboratories | $18.17 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $17.37 | 2023 | Gvoke Hypopen |
| Lucid Diagnostics INC. | $16.50 | 2024 | |
| Ardelyx, INC. | $14.61 | 2025 | Ibsrela |
| Genentech USA, INC. | $5.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.